Welcome to our dedicated page for Intellipharmaceu news (Ticker: IPCIF), a resource for investors and traders seeking the latest updates and insights on Intellipharmaceu stock.
Intellipharmaceutics International Inc. (IPCIF) is a pharmaceutical innovator specializing in advanced controlled-release drug delivery systems through its patented Hypermatrix™ technology. This page serves as the definitive source for verified corporate announcements, regulatory developments, and research breakthroughs.
Investors and industry professionals will find timely updates on ANDA/NDA filings, partnership agreements, and clinical trial progress across the company's generic and novel drug pipelines. Our curated collection includes earnings reports, manufacturing updates, and scientific advancements related to abuse-deterrent formulations and targeted-release therapies.
Bookmark this page for structured access to IPCIF's latest strategic initiatives in pharmaceutical development, including technology licensing agreements and international regulatory submissions. All content is maintained to meet strict journalistic standards for accuracy in financial reporting.
On June 14, 2024, Intellipharmaceutics announced that its stock (OTCQB:IPCIF, TSX:IPCI.H) will be downgraded to the OTC Expert Market on June 17, 2024, due to the failure to file Form 20-F for the fiscal year ending November 30, 2023.
The Expert Market quotes are 'Unsolicited Only,' restricting public viewings to broker-dealers and sophisticated investors. The company is also under a cease trade order from the Ontario Securities Commission since March 5, 2024, due to non-filing of important financial statements and forms.
There is no assurance that Intellipharmaceutics will rectify these issues promptly or at all.
Intellipharmaceutics International Inc. (OTCQB:IPCIF) reported its operational results for the three and nine months ending August 31, 2022. The company achieved revenues of $19,068, attributed to a license agreement with Taro Pharmaceuticals, compared to $Nil in Q3 2021. Net loss decreased to $296,043 per share, from $1,264,305 in the previous year. R&D expenses declined to $626,069, while SG&A expenses fell to $(292,296). As of the reporting date, cash balance stood at $79,649. The company highlighted the need for additional funding for continued R&D and product commercialization.
FAQ
What is the current stock price of Intellipharmaceu (IPCIF)?
What is the market cap of Intellipharmaceu (IPCIF)?
